Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma

Expert Rev Hematol. 2024 Jun;17(6):197-200. doi: 10.1080/17474086.2024.2353751. Epub 2024 May 11.
No abstract available

Keywords: BCMA; Myeloma; bispecific antibodies; elranatamab; teclistamab.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Bispecific* / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • B-Cell Maturation Antigen* / antagonists & inhibitors
  • B-Cell Maturation Antigen* / metabolism
  • Drug Resistance, Neoplasm
  • Humans
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / therapy
  • Recurrence

Substances

  • Antibodies, Bispecific
  • B-Cell Maturation Antigen
  • Antibodies, Monoclonal, Humanized